Our President and COO Kathryn Corzo talks with editor Brian Buntz from Drug Discovery & Development.
30.08.2023Our President and COO Kathryn Corzo talks with editor Brian Buntz from Drug Discovery & Development.
Our President and COO Kathryn Corzo talks with editor Brian Buntz from Drug Discovery & Development.
30.08.2023Our President and COO Kathryn Corzo talks with editor Brian Buntz from Drug Discovery & Development.
Partnership to build a platform for the development of safer and more efficient genetic engineering of human cells for cell therap...
24.08.2023New iPSC-derived opti-ox™ powered disease model cells with the potential to advance frontotemporal dementia research and drug disc...
23.08.2023BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery & manufacture of regulatory T cell...
03.08.2023In this episode of the SynBioBeta podcast, bit.bio CEO Mark Kotter discusses the influence synthetic biology is having on the futu...
27.07.2023bit.bio secures foundational United States patent for opti-ox, its cell programming technology that uses genomic safe harbour site...
26.07.2023bit.bio's President and COO named as one of the 20 women reshaping biopharma R&D in 2023 report.
21.07.2023An article on synbio in the Summer 2023 issue of Science in Parliament magazine. Authored by our founder and CEO Mark Kotter.
17.07.2023bit.bio launches two new human cell disease models to advance discovery and development of treatments for Duchenne muscular dystro...
12.07.2023